JPH03227907A - Skin cosmetic base - Google Patents
Skin cosmetic baseInfo
- Publication number
- JPH03227907A JPH03227907A JP2326090A JP2326090A JPH03227907A JP H03227907 A JPH03227907 A JP H03227907A JP 2326090 A JP2326090 A JP 2326090A JP 2326090 A JP2326090 A JP 2326090A JP H03227907 A JPH03227907 A JP H03227907A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- cosmetic base
- skin cosmetic
- magnesium salt
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 150000007524 organic acids Chemical class 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- -1 ester magnesium salt Chemical class 0.000 claims abstract description 6
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 238000002845 discoloration Methods 0.000 abstract description 9
- 230000001953 sensory effect Effects 0.000 abstract description 8
- 239000007864 aqueous solution Substances 0.000 abstract description 7
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract description 6
- 238000001556 precipitation Methods 0.000 abstract description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 abstract description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 4
- 239000006210 lotion Substances 0.000 abstract description 4
- 239000011975 tartaric acid Substances 0.000 abstract description 4
- 235000002906 tartaric acid Nutrition 0.000 abstract description 4
- 239000006071 cream Substances 0.000 abstract description 2
- 239000004310 lactic acid Substances 0.000 abstract description 2
- 235000014655 lactic acid Nutrition 0.000 abstract description 2
- 239000000049 pigment Substances 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 239000002304 perfume Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 229940124543 ultraviolet light absorber Drugs 0.000 abstract 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 description 11
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 159000000003 magnesium salts Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- NGPNWUWGVIIIDG-LEJBHHMKSA-L magnesium;[(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-yl] phosphate Chemical class [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1OP([O-])([O-])=O NGPNWUWGVIIIDG-LEJBHHMKSA-L 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 230000021148 sequestering of metal ion Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、L−アスコルビン酸リン酸エステルマグネシ
ウム塩水溶液にカルボキシル基と水酸基の数の比が1で
ある有機酸またはその塩を併用してなる保存安定性(沈
殿物、外観)、官能特性(匂い)に優れた皮膚化粧料に
関する。Detailed Description of the Invention [Industrial Application Field] The present invention provides an organic acid having a carboxyl group to hydroxyl group ratio of 1 or a salt thereof to an aqueous L-ascorbic acid phosphate magnesium salt solution. The present invention relates to skin cosmetics with excellent storage stability (precipitate, appearance) and sensory characteristics (odor).
〔従来の技術及び発明が解決しようとする課題〕L−ア
スコルヒン酸リン酸エステルマグネシウム塩は水溶性で
経皮吸収されると生体内でフォスファターゼなどの酵素
によって加水分解されLアスコルビン酸が遊離しヒクミ
ンC活性を示す。[Prior art and problems to be solved by the invention] L-ascorbic acid phosphate ester magnesium salt is water-soluble and when absorbed transdermally, it is hydrolyzed in vivo by enzymes such as phosphatase to liberate L-ascorbic acid and form Hikmin. It shows C activity.
このことによって皮膚化粧料にL−アスコルビン酸リン
酸エステルマグネシウム塩がひんばんに配合されている
。As a result, L-ascorbic acid phosphate ester magnesium salt is frequently incorporated into skin cosmetics.
しかしながら、L−アスコルビン酸リン酸エステルマグ
ネシウム塩水溶液は経時的に沈殿物(おり)が発生した
り変色しその経皮吸収性が低下する問題が指摘されてい
る。However, it has been pointed out that an aqueous solution of L-ascorbic acid phosphate magnesium salt has a problem in that a precipitate is generated or discolored over time, and its transdermal absorbability is reduced.
この課題の解決策として、例えば特開昭61−1302
05にはアスコルビン酸誘導体に炭素数6〜10のジカ
ルボン酸を配合することによって沈殿・変色の生じない
安定化した水系組成物が開示されている。As a solution to this problem, for example, JP-A-61-1302
No. 05 discloses a stabilized aqueous composition that does not cause precipitation or discoloration by blending an ascorbic acid derivative with a dicarboxylic acid having 6 to 10 carbon atoms.
しかし、この特開昭61−130205に用いている炭
素数6〜10のジカルボン酸はアルコールや液状油に溶
解するが水−・の溶解性ば必ずしもよくなく水系への配
合は特に低温時、困難で結晶が析出する。However, although the dicarboxylic acid having 6 to 10 carbon atoms used in JP-A-61-130205 is soluble in alcohol and liquid oil, its solubility in water is not necessarily good and it is difficult to incorporate it into an aqueous system, especially at low temperatures. Crystals precipitate.
また、特開昭62−63597ばI、−アスコルビン酸
リン酸エステルマグネシウム塩水溶液に有機カルボン酸
またはその塩を配合することによって当該水溶液のおり
を防止するというものだが、そこで使用される有機カル
ボン酸またはその塩ばコハク酸ナトリウム、フマール酸
すI・リウム、クエン酸ナトリウム、ピリドンカルボン
酸ナトリウム、エデト酸ナトリウム、グリチルリチン酸
、グリチルリチン酸アンモニウム、グリチルリチン酸カ
リウムなどをあげているが、その効果は充分でない。In addition, JP-A No. 62-63597 discloses that by blending an organic carboxylic acid or its salt into an aqueous solution of ascorbic acid phosphate magnesium salt, the aqueous solution is prevented from oozing. Or its salts include sodium succinate, sodium fumarate, sodium citrate, sodium pyridonecarboxylate, sodium edetate, glycyrrhizic acid, ammonium glycyrrhizinate, potassium glycyrrhizinate, etc., but their effects are not sufficient. .
さらに、特開昭63−243014はL−アスコルビン
酸−2−リン酸エステルマグネシウム塩に非イオン界面
活性剤、電解質を配合する皮膚化粧料であるが、そこで
の電解質もまたクエン酸コハク酸の塩をあげている。し
かしながら、Lアスコルビン酸−2−リン酸エステルマ
グネシウム塩の安定性(沈殿、変色)は充分でない。Furthermore, JP-A No. 63-243014 discloses a skin cosmetic containing magnesium salt of L-ascorbic acid-2-phosphate, a nonionic surfactant, and an electrolyte, but the electrolyte therein is also a salt of citric and succinic acid. are giving. However, the stability (precipitation, discoloration) of L-ascorbic acid-2-phosphate magnesium salt is not sufficient.
本発明は前記の問題に鑑み鋭意研究したところ、L−ア
スコルビン酸リン酸エステルマグネシウム塩水溶液に特
に限定された有機酸またはその塩、すなわちカルボキシ
ル基と水酸基の数の比が1である有機酸またはその塩を
併用することによってL−アスコルビン酸リン酸エステ
ルマグネシウム塩水溶液の経時変化(沈殿物の発生や変
色、変臭)を防止できることを見いだし本発明を完成し
た。The present invention has been made through extensive research in view of the above-mentioned problems.The present invention has been made based on an aqueous solution of L-ascorbic acid phosphate magnesium salt. The present invention has been completed by discovering that by using the salt in combination, it is possible to prevent changes over time (formation of precipitates, discoloration, and odor) of an aqueous solution of L-ascorbic acid phosphate magnesium salt.
すなわち、本発明はL−アスコルビン酸リン酸エステル
マグネシウム塩、カルボキシル基と水酸基の数の比が1
である有機酸またはその塩、および水を必須成分として
含有してなる皮膚化粧料である。That is, the present invention provides a magnesium salt of L-ascorbic acid phosphate, in which the ratio of the number of carboxyl groups to hydroxyl groups is 1.
A skin cosmetic containing an organic acid or a salt thereof and water as essential ingredients.
本発明に用いられるカルボキシル基と水酸基の数の比が
1である有機酸ば酒石酸、乳酸、グリコル酸等およびそ
のカリウム塩、すトリウム塩カルシウム塩等があげられ
、これらを1種または2種以上が使用される。また、上
記有機酸はその光学活性体やラセミ化をも含む。Organic acids having a carboxyl group to hydroxyl group number ratio of 1 include tartaric acid, lactic acid, glycolic acid, etc., and their potassium salts, strium salts, calcium salts, etc., and one or more of these may be used in the present invention. is used. Further, the above-mentioned organic acids include optically active forms and racemized forms thereof.
本発明に用いられるし一アスコルヒン酸リン酸エステル
マグネシウム塩の配合量は化粧料の総量を基準として好
ましくは0.1〜10重量%、特に好ましくは1−5重
量%の範@Iである。O,1重量%以下では化粧効果が
期待できなく、10重用%以上では溶解性がわるく沈殿
等の原因となる。The amount of monoascorchic acid phosphate magnesium salt used in the present invention is preferably in the range of 0.1 to 10% by weight, particularly preferably 1 to 5% by weight, based on the total amount of the cosmetic. If O is less than 1% by weight, no cosmetic effect can be expected, and if it is more than 10% by weight, the solubility is poor and may cause precipitation.
本発明に用いられるカルボキシル基と水酸基の数の比が
1である有機酸の配合量は本皮膚化粧料の総量を基準と
して好ましくは0.1〜5.0重量%、特に好ましくは
0.5〜3.0重量%の範囲である。The amount of the organic acid having a carboxyl group to hydroxyl group ratio of 1 used in the present invention is preferably 0.1 to 5.0% by weight, particularly preferably 0.5% by weight, based on the total amount of the skin cosmetic. -3.0% by weight.
また、2つ以上を組み合わせても前記の範囲内である。Furthermore, a combination of two or more is also within the above range.
0.1重量%以下ではL−アスコルビン酸リン酸エステ
ルマグネシウム塩水溶液の経時変化を十分防止できず、
5.0重量%以上では本皮膚化粧料の官能特性がわるく
なると共に皮膚刺激がでる傾向にある。If it is less than 0.1% by weight, changes over time of the L-ascorbic acid phosphate magnesium salt aqueous solution cannot be sufficiently prevented;
If it exceeds 5.0% by weight, the sensory properties of the skin cosmetic will deteriorate and skin irritation will tend to occur.
本発明の皮膚化粧料には上記の必須成分の他に、必要に
応じて色素、香料、防腐剤、界面活性剤紫外線吸収剤、
酸化防止剤、保湿剤、高分子、金属イオン封鎖剤等を本
発明の目的を達成する範囲内で適宜配合せしめることが
できる。In addition to the above-mentioned essential ingredients, the skin cosmetics of the present invention may optionally include pigments, fragrances, preservatives, surfactants, ultraviolet absorbers,
Antioxidants, humectants, polymers, metal ion sequestering agents, etc. can be appropriately incorporated within the range that achieves the object of the present invention.
本発明の皮膚化粧料は化粧水、乳液、クリームパンク、
エツセンス等に適用される。The skin cosmetics of the present invention include lotions, milky lotions, cream punctures,
Applicable to essence etc.
以下、実施例について説明する。 Examples will be described below.
= 5 実施例に示す配合量の単位は重量%を意味する。= 5 The unit of compounding amount shown in the examples means weight %.
実施例において調べた保存安定性試験(沈殿物外観)、
官能特性試験(匂い)の試験方法は下記の通りである。Storage stability test (precipitate appearance) investigated in Examples,
The test method for the sensory characteristic test (odor) is as follows.
(1) 保存安定性試験
(沈殿物)
試料を40°C1室温にそれぞれ6ケ月間放置し、その
沈殿物の有無を専門検査員3人によって肉眼にて調べた
。評価基準は次のように3段階にて行った。(1) Storage stability test (precipitate) Each sample was left at room temperature of 40°C for 6 months, and the presence or absence of precipitate was visually examined by three specialized inspectors. The evaluation criteria were in three stages as follows.
1、 沈殿物がない(良好)
2、微かな沈殿物がある(やや不良)
3、 沈殿物がある(不良)
(外観)
上記の試料の外観、つまり着色度合いを専門検査員3人
によって肉眼にて調べた。評価基準は次のように3段階
にて行った。1. There is no precipitate (good) 2. There is a slight precipitate (slightly poor) 3. There is a precipitate (poor) (Appearance) Three specialized inspectors visually inspected the appearance of the above sample, that is, the degree of coloration. I investigated. The evaluation criteria were in three stages as follows.
1、 変色しないか、微かに変色する(良好)2、 黄
色に若干、変色するくやや良好)3、 褐色に変色する
(不良)
(2) 官能特性試験
(匂い)
試料を塗布したときの匂いを専門検査員3人によって調
べ、総合評価した。評価基準は次のように3段階にて行
った。1. No discoloration or slight discoloration (good) 2. Slight yellow discoloration (slightly good) 3. Discoloration to brown (poor) (2) Sensory characteristics test (odor) Odor when the sample is applied were examined by three specialized inspectors and comprehensively evaluated. The evaluation criteria were in three stages as follows.
1、 はとんど匂いがない(良好)
2、 わずかなぐいかある(やや良好)3、 匂いがあ
る(不良)
実施例1〜7.比較例1
第1表記載の処方(重量%)で皮膚化粧料を調製した。1. There is almost no odor (good) 2. There is a slight smell (slightly good) 3. There is an odor (poor) Examples 1 to 7. Comparative Example 1 A skin cosmetic was prepared using the formulation (% by weight) shown in Table 1.
カルボキシル基と水酸基の数の比が1である特定の有機
酸塩には乳酸塩(ナトリウム、カリウム、カルシウム)
を用いた。Certain organic acid salts with a ratio of carboxyl groups to hydroxyl groups of 1 include lactate (sodium, potassium, calcium).
was used.
表中成分1〜5を6に溶解し皮膚化粧料を調製し、その
特性を第1表に併せて示した。Ingredients 1 to 5 in the table were dissolved in 6 to prepare a skin cosmetic, and its properties are also shown in Table 1.
表1から判るように本発明に従いL−アスコルビン酸リ
ン酸エステルマグネシウム塩にカルボキシル基と水酸基
の数の比が1である乳酸ナトリウム、乳酸カリウム、乳
酸カルシウム及び水を含有する実施例の皮膚化粧料は保
存安定性(沈殿物外観)
官能特性
(匂い)
に優れていた。As can be seen from Table 1, the skin cosmetic of the example contains sodium lactate, potassium lactate, calcium lactate, and water in which the ratio of the number of carboxyl groups to hydroxyl groups is 1 in L-ascorbic acid phosphate magnesium salt according to the present invention. had excellent storage stability (precipitate appearance) and sensory characteristics (odor).
他方、 乳酸塩を欠く 比較例 ■ の皮膚化粧料は保存安定性 実施例8〜15.比較例2〜4 第2表記載の処方(重量%)で皮膚化粧料を調製した。On the other hand, lacks lactate Comparative example ■ The storage stability of skin cosmetics Examples 8-15. Comparative examples 2 to 4 Skin cosmetics were prepared according to the formulations (% by weight) listed in Table 2.
カルボキシル基と水酸基の数の比が1である特定の有機
酸及びその塩を一種もしくは二種以上組ミあわせて用い
た。One or more specific organic acids and salts thereof having a carboxyl group to hydroxyl group ratio of 1 were used.
表中成分1〜11を14に溶解し、ついで成分12.1
3を溶解したものを加え皮膚化粧料を調製しその特性を
第2表に併せて示した。Components 1 to 11 in the table are dissolved in 14, then component 12.1
A skin cosmetic was prepared by adding a solution of No. 3, and its properties are also shown in Table 2.
表2から判るように本発明に従いI、−アスコルビン酸
リン酸エステルマグネシウム塩にカルボキシル基と水酸
基の数の比が1である酒石酸または酒石酸塩、ゲルコー
ル酸塩を一種もしくは二種以上及び水を含有する実施例
6〜15の皮膚化粧料は保存安定性、官能特性いずれも
優れていた。As can be seen from Table 2, according to the present invention, I, -ascorbic acid phosphate magnesium salt contains one or more tartaric acid, tartrate, or gelcholate having a ratio of carboxyl groups to hydroxyl groups of 1, and water. The skin cosmetics of Examples 6 to 15 were excellent in both storage stability and sensory properties.
それに対し、クエン酸塩(カルボキシル基:水酸基−3
:l)、cM!−リンゴ酸塩(2:1)コハク酸塩(2
: O)を酒石酸または酒石酸塩の代わりに用いた比較
例2〜4はいずれも保存安定0
〔発明の効果〕
以上、記載のごとく本発明の皮膚化粧料は経口によって
L−アスコルビン酸リン酸エステルマグネシウム塩の沈
殿物の発生や変色がなく保存安定性に優れ、かつ、匂い
の変化もないか、もしくは少なく官能特性に優れている
ことは明らかである。On the other hand, citrate (carboxyl group: hydroxyl group -3
:l), cm! -malate (2:1) succinate (2:1)
: All of Comparative Examples 2 to 4 in which O) was used in place of tartaric acid or tartrate had a storage stability of 0. [Effects of the Invention] As described above, the skin cosmetic of the present invention can be administered orally to L-ascorbic acid phosphate. It is clear that it has excellent storage stability with no precipitation or discoloration of magnesium salts, and has excellent sensory characteristics with no or little change in odor.
■■
Claims (1)
カルボキシル基と水酸基の数の比が1である有機酸また
はその塩、および水を必須成分として含有してなる皮膚
化粧料。L-ascorbic acid phosphate ester magnesium salt,
A skin cosmetic comprising an organic acid or a salt thereof having a ratio of carboxyl groups to hydroxyl groups of 1, and water as essential ingredients.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2326090A JP2883662B2 (en) | 1990-01-31 | 1990-01-31 | Skin cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2326090A JP2883662B2 (en) | 1990-01-31 | 1990-01-31 | Skin cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03227907A true JPH03227907A (en) | 1991-10-08 |
JP2883662B2 JP2883662B2 (en) | 1999-04-19 |
Family
ID=12105634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2326090A Expired - Lifetime JP2883662B2 (en) | 1990-01-31 | 1990-01-31 | Skin cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2883662B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05331020A (en) * | 1992-05-26 | 1993-12-14 | Kanebo Ltd | Skin cosmetic |
CN1069904C (en) * | 1997-06-04 | 2001-08-22 | 株式会社太平洋 | Water stable L-ascorbic acid derivative and its preparation method, and beauty composition containing same for making face white-skinned |
JP2007055943A (en) * | 2005-08-25 | 2007-03-08 | Kyoei Kagaku Kogyo Kk | Ascorbic acid 2-phosphate magnesium composition and cosmetic containing the same |
-
1990
- 1990-01-31 JP JP2326090A patent/JP2883662B2/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05331020A (en) * | 1992-05-26 | 1993-12-14 | Kanebo Ltd | Skin cosmetic |
CN1069904C (en) * | 1997-06-04 | 2001-08-22 | 株式会社太平洋 | Water stable L-ascorbic acid derivative and its preparation method, and beauty composition containing same for making face white-skinned |
JP2007055943A (en) * | 2005-08-25 | 2007-03-08 | Kyoei Kagaku Kogyo Kk | Ascorbic acid 2-phosphate magnesium composition and cosmetic containing the same |
Also Published As
Publication number | Publication date |
---|---|
JP2883662B2 (en) | 1999-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4287214A (en) | Dithranol compositions stabilized with alpha hydroxyacids | |
US5728391A (en) | Hyaluronic acid and its salt for treating skin diseases | |
EP0934742B1 (en) | Anti-microbial cleansers | |
KR19990022343A (en) | Topical vehicle containing dissolved and stabilized azelaic acid | |
JPS6323166B2 (en) | ||
WO2020028820A1 (en) | Topical compositions and methods of preparation and use | |
US5098717A (en) | Method of treatment for pruritus | |
US5654341A (en) | Low pH skin-treatment composition | |
JP2009510087A (en) | Stable ascorbic acid composition | |
JPS588007A (en) | Cosmetic for making skin soft | |
US20060100178A1 (en) | Dermal agent | |
KR20060020630A (en) | Topical treatment of sebum related skin conditions | |
CA1250236A (en) | Gel-form topical antibiotic compositions | |
CA1129772A (en) | Stable erythromycin solution | |
JPH03236320A (en) | Skin drug for external use | |
JPH03227907A (en) | Skin cosmetic base | |
US2588324A (en) | Dental paste | |
JPH0418010A (en) | W/o/w type emulsified cosmetic | |
JPS5869806A (en) | Cosmetic lotion containing stable collagen | |
JP2002003330A (en) | Cosmetic | |
JP2780803B2 (en) | External preparation for skin | |
JP2002060315A (en) | Ascorbic acid-containing thickening composition | |
JPH0363208A (en) | Cosmetic | |
JPH05331020A (en) | Skin cosmetic | |
JPH10279421A (en) | Preparation for external use for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080205 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090205 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090205 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100205 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term |